Holen Sie sich die Stockscreener-App
11.48
0.17%
-0.02
Handel nachbörslich:
11.48
Daxor Corporation Aktie (DXR) Neueste Nachrichten
DXR: Direct blood volume analysis drives improved outcomes and rapid revenue growth in a vast market - TradingView
Daxor (DXR) Unveils Portable Blood Volume Analyzer at Critical C - GuruFocus
Daxor Corporation Showcases New Portable Blood Volume Analyzer - marketscreener.com
Daxor to debut portable blood volume analyzer at SCCM Critical Care Congress - TipRanks
Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress - GlobeNewswire
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 - GlobeNewswire
Market Overview: Will Murano Global Investments Plc Equity Warrant benefit from rate cuts2026 Top Gainers & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
What analyst consensus says on Daxor Corporation stockExit Point & Fast Moving Trade Plans - Naître et grandir
Layoff Watch: Is Daxor Corporation a turnaround storyGap Up & Safe Entry Trade Reports - baoquankhu1.vn
Daxor (NYSEAMERICAN:DXR) Share Price Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
European Stocks Set for Mixed Opening Amid Geopolitical Tensions - Intellectia AI
DXR SEC FilingsDAXOR CORP 10-K, 10-Q, 8-K Forms - Stock Titan
Daxor Corporation Reports 2025 Fiscal Year Results, Operating Revenue Up 45%, Net Asset Value Rises to $9.07 per Share - marketscreener.com
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders - Bitget
Daxor reports 45% revenue growth, plans regulatory shift - Investing.com
Daxor Corporation CEO and President Michael Feldschuh provides corporate update in letter to shareholders - marketscreener.com
Daxor (DXR) Records Strong Growth and Regulatory Changes in 2025 - GuruFocus
Daxor issues update in Letter to Shareholders - TipRanks
Daxor (DXR) Secures FDA Clearance for Advanced Blood Volume Anal - GuruFocus
Daxor Corporation CEO And President Michael Feldschuh Provides Corporate Update In Letter To Shareholders - TradingView
7-pound blood volume analyzer wins FDA clearance, gains hospital users - Stock Titan
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share - marketscreener.com
Daxor Corporation Reports 2025 Fiscal Year Results: - GlobeNewswire
DXR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
FDA‑cleared BVA boosts momentum; Daxor (NASDAQ: DXR) posts NAV $9.07 and $46M operating valuation - Stock Titan
Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Short Interest in Daxor Corporation (NASDAQ:DXR) Decreases By 44.0% - MarketBeat
Daxor Corporation (DXR) Competitors - Meyka
Daxor (NASDAQ:DXR) vs. Addus HomeCare (NASDAQ:ADUS) Financial Survey - Defense World
EBIT per share of Daxor Corporation – NASDAQ:DXR - TradingView
Daxor (NYSEAMERICAN:DXR) Share Price Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Daxor continues strategic expansion, opens new BVA program in Tennessee - TipRanks
Daxor (DXR) Expands BVA Program to Southern Middle Tennessee - GuruFocus
Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee - The Manila Times
Gainers Report: Will LightPath Technologies Inc benefit from government policy2025 Key Lessons & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Daxor (NYSEAMERICAN:DXR) Stock Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Is Daxor Corporation stock a safe haven assetWeekly Profit Summary & Stock Portfolio Risk Control - mfd.ru
Can Daxor Corporation stock double in next 5 yearsTrade Risk Report & Fast Entry and Exit Trade Plans - mfd.ru
Daxor to shift regulatory reporting from Investment Company Act By Investing.com - Investing.com South Africa
Winners Losers: Is Daxor Corporation a turnaround storyWeekly Earnings Recap & Reliable Price Breakout Alerts - baoquankhu1.vn
Daxor Corp reaffirms focus on blood volume analysis technology - marketscreener.com
Daxor Corp Reaffirms Focus On Blood Volume Analysis Technology - TradingView
Daxor to transition to Securities Exchange Act of 1934 reporting company - TipRanks
Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business - The Manila Times
Daxor Corporation Announces Transition To Securities - GlobeNewswire
Daxor (NYSEAMERICAN:DXR) Stock Passes Below 200 Day Moving AverageTime to Sell? - MarketBeat
Trading the Move, Not the Narrative: (DXR) Edition - Stock Traders Daily
Daxor (NASDAQ:DXR) Stock Price Up 0.6%Time to Buy? - MarketBeat
Contrasting Daxor (NASDAQ:DXR) and Quest Diagnostics (NYSE:DGX) - Defense World
Aug Swings: Should I invest in Daxor Corporation before earningsPortfolio Profit Report & Safe Entry Point Alerts - baoquankhu1.vn
Guidance Update: Is Daxor Corporation a turnaround storySwing Trade & Stock Timing and Entry Methods - baoquankhu1.vn
What is the PEG ratio of Daxor CorporationOil Prices & Safe Entry Momentum Stock Tips - mfd.ru
What are Daxor Corporation’s technical support levels2025 Growth vs Value & Accurate Intraday Trading Signals - mfd.ru
Aug Outlook: Will Daxor Corporation stock go up in YEAR2025 Buyback Activity & Real-Time Buy Zone Alerts - baoquankhu1.vn
Daxor completes $8.1 million direct offering of common stock on Nasdaq - Investing.com Australia
Daxor Signs Multiple Material Agreements - TradingView
Daxor Corporation Announces $9 Million Registered Direct Offering - Sahm
Daxor Releases Updated Investor Presentation to Public Markets - The Globe and Mail
0.97%
1.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):